FDA
-
-
-
-
-
-
-
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
-
-
-
-
-
-
-
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
-
-
-
-
-
-
-
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
-
-
-
-
-
-
-
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
-
-
-
-
-
-
-
Innoviva (INVA) Announces FDA Approval of XACDURO
-
-
-
-
-
-
-
Innoviva (INVA) Confirms Stock Trading Halted Today Ahead of FDA Panel Meeting for Sulbactam-Durlobactam
-
-
-
-
-
-
-
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
-
322,214 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

